In PDAC, KRAS mutation is critical to control tumor metabolism through promotion of glucose uptake and channeling of glucose intermediates into the hexosamine biosynthesis and the nonoxidative arm of pentose phosphate pathway 16. This evidence concerns the gene KRAS and neoplasm.